

**This listing of claims will replace all prior versions, and listings, of claims in the application:**

Claim 1 (currently amended): In a therapeutic composition comprising a bactericidal/permeability-increasing protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant **and EDTA**.

Claim 2 (Cancelled).

Claim 3 (original): The improved composition of claim 1 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

Claim 4 (Cancelled).

Claim 5 (withdrawn): In a method for treating a bacterial infection comprising administering a composition of BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improvement comprising administering a therapeutic composition of BPI protein product and bactericidal-activity-enhancing poloxamer surfactant.

Claim 6 (withdrawn): The improved method of claim 5 wherein the therapeutic composition further comprises EDTA.

Claim 7 (withdrawn): The improved method of claim 5 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

Claim 8 (withdrawn): The improved method of claim 5 further comprising administering an antibiotic.

Claim 9 (currently amended): A composition for inhibiting bacterial and fungal growth comprising a BPI protein product, ~~and~~ a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant **and EDTA**.

Claim 10 (Cancelled).

Claim 11 (original): The composition of claim 9 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

Claim 12 (withdrawn): A method for inhibiting bacterial and fungal growth comprising treating the bacteria or fungus with a composition of a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.

Claim 13 (withdrawn): The method of claim 12 wherein the composition further comprises EDTA.

Claim 14 (withdrawn): The method of claim 12 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.